A study of the efficacy of milnacipran in patients with major depressive disorder (MDD) after SSRI treatment failure, and biological research for MDD using peripheral blood.
Not Applicable
- Conditions
- Major depressive disorder
- Registration Number
- JPRN-UMIN000003516
- Lead Sponsor
- Department of Psychiatry, Chiba University Graduate School of Medicine, Division of Psychiatry, Chiba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) treating with selegiline hydrochloride 2) Allergy against milnacipran 3) patients with urinary retension 4) pregnant or breast-feeding women or women, who may be pregnant 5) significant risk of suicide 6) patients with dementia, bipolar or psychotic disorders, those with a primary diagnosis of obsessive-compulsive disorder or an eating disorder. 7) Patient whom examination doctor judge improper as a trial subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exploratory examination of short- and long-term effects of switching to milnacipran on the relationship between clinical outcomes and blood molecules levels.
- Secondary Outcome Measures
Name Time Method 1) The rate of Response by Hamilton Depression Rating Scale (HDRS-17) 2) The rate of Remission by Hamilton Depression Rating Scale (HDRS-17) 3) The rate continuation of treatment 4) Remission and response rate by QIDS-SR 5) Social Adaptation Self-evaluation Scale (SASS). 6) Clinical Global Inpression (CGI). 7) Montogomery-Asberg Depression rating Scale (MADRS). 8) Safety 9) Neurotransmitters, Neuropeptide, and others in peripheral blood.